Update from @ascocancer.bsky.social #ASCO26: Pumitamig + chemotherapy delivered promising early activity in first-line advanced #NSCLC across histologies and PD-L1 expression levels. #lcsm
Read more: www.onclive.com/view/pumitam...
Pumitamig plus chemotherapy generated strong responses across NSCLC subtypes and PD-L1 levels with manageable safety in ROSETTA Lung-02.